Outpatient Treatment for COVID-19


Alberta Health Services and Alberta Health are rolling out the administration of Sotrovimab, a new monoclonal antibody treatment for COVID-19 that was recently approved by Health Canada. Health Canada has authorized the sale of this drug based on limited clinical testing in humans and/or quality information.

What Is Sotrovimab?

Sotrovimab is a new drug that was developed specifically for treating COVID-19 patients with mild to moderate symptoms. It is the first treatment to be offered to outpatients in Alberta and is administered by intravenous infusion within five days of symptom onset.

Am I Eligible for Sotrovimab Treatment?

Sotrovimab is for use in patients who have a RT-PCR confirmed COVID-19 infection if they can receive the treatment within five days of symptom onset AND they are:

1. Unvaccinated and are:

  • Age 55 and older


  • Age 18 and older with a pre-existing health condition including
    • diabetes (taking medication for treatment)
    • obesity (BMI >30)
    • chronic kidney disease (estimated glomerular filtration rate, <60 ml per minute per 1.73 m2 of body-surface area)
    • congestive heart failure (New York Heart Association class II, III, or IV)
    • chronic obstructive pulmonary disease, and moderate-to-severe asthma


  • pregnant


2. Immunocompromised, due to one of the following reasons (vaccinated or unvaccinated):

  • have received a transplant
  • is an oncology patients who has received a dose of any IV or oral chemotherapy or other immunosuppressive treatment since December 2020
  • has an inflammatory condition (e.g. rheumatoid arthritis, lupus, inflammatory bowel disease) receiving a dose of any systemic immunosuppressive treatment since December 2020.

If you believe you are eligible, please call Health Link at 1-844-343-0971 and leave a message. Health Link staff will call you back and ask you some questions before referring you to a health professional who will determine if you are eligible, get your consent and book your appointment.

If you have any questions about the eligibility status, additional information can be found in the Patient FAQ.

How Is It Administered?

EMS Mobile Integrated Health (MIH) will administer the treatment by IV infusion in patients’ homes or continuing care facility. In areas not serviced by EMS MIH, patients will booked for an appointment at an AHS site. Patients will receive the IV infusion treatment over one hour, and will be observed for another hour post-treatment.

Find Out If You Qualify

If you have tested positive for COVID-19 and your symptoms began less than four days ago, please call 1-844-343-0971 to find out if you qualify to receive Sotrovimab.

Sotrovimab is reported to have the potential to prevent one hospital admission for every 20 patients who receive treatment.

Sotrovimab is not a replacement for COVID-19 vaccination. Albertans are strongly encouraged to get fully vaccinated against COVID-19. This is a treatment that is available to those who are at a higher risk of worsening symptoms from the disease and who may require hospitalization.

Next Steps & Future Access

AHS is making every effort to ensure timely and fair access for all Albertans who qualify to receive this treatment; however, it is being rolled out in phases that we recognize may initially exclude some qualified patients. Future phases of the rollout will include an expanded patient criteria.